AI Insight
The European Medicines Agency has granted regulatory approval for an oral tablet formulation of semaglutide, marketed as Wegovy, developed by Novo Nordisk for the treatment of obesity. This approval represents an expansion of the existing Wegovy product line, which was previously available only as a subcutaneous injection. The oral formulation offers patients an alternative administration route for the GLP-1 receptor agonist medication.
Why it matters
An approved pill form of Wegovy may improve patient adherence and accessibility by eliminating the barrier of self-injection, potentially broadening the reach of pharmacological obesity treatment across the EU population.
Novo Nordisk has obtained approval for the pill form of its popular Wegovy anti-obesity drug in the European Union, the bloc’s medicines regulator said on Friday.
Source: EU regulator approves pill form of Novo Nordisk's Wegovy weight loss drug